Steve Carchedi

Director- Board of Directors

Sunesis Pharmaceuticals

Having held key positions at several leading multinational pharmaceutical companies, Steve Carchedi offers more than 25 years of industry experience, with proven accomplishment in specialty pharmaceuticals focused on Oncology, Neurology, Urology, Endocrinology and Cardiology. Mr. Carchedi was CMO for General Electric (GE) Healthcare where he leads worldwide marketing for the $1.8 Billion Medical Diagnostics (MDX) business focused on the development and commercialization of pharmaceutical diagnostic (in vivo and in vitro) and Radiopharmaceutical agents for Oncology, Neurology and Cardiology. Previously At Endo Pharmaceuticals, he served as SVP Specialty Business Unit and headed commercial operations for the company’s $100MM specialty pharmaceutical business. This position included responsibility for strategic development, planning and execution for Urology, Endocrinology and Oncology (UEO) – along with the leadership of sales and marketing functions. Prior to joining Endo, Mr. Carchedi was Head of Commercial Operations (COO) at Enzon Pharmaceuticals, a specialty oncology company, reporting directly to the Chairman of the Board. Among his leadership responsibilities were Sales, Marketing, Medical Affairs, Strategy, Operations and P & L. He was a member of Enzon’s Senior Management Team and was a driving force in devising and implementing the company’s business and marketing strategies, while leading a management team of over 100 employees. Before his work at Enzon, Mr. Carchedi served as Franchise Vice President, Johnson & Johnson McNeil Consumer & Specialty Pharmaceuticals. He led commercial efforts for McNeil Specialty Pharmaceuticals, a prominent pediatric company dedicated to developing novel pharmaceutical products that improve the lives of children. During his tenure at McNeil, Mr. Carchedi led the company to a record level of gross sales, exceeding $1.0 Billion. As the Global Marketing Leader for Johnson & Johnson Oncology, he led the worldwide launch of VELCADE® (Bortezomib), which received the prestigious Prix Galien Award and now treats Multiple Myeloma in over 80 countries. Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.